Copy the page URI to the clipboard
Chataway, Joanna; Tait, Joyce and Wield, David
(2007).
DOI: https://doi.org/10.1080/09537320701521465
Abstract
Some industrially advanced developing countries have, in the last decades, built substantial pharmaceutical scientific and industrial capabilities. The more advanced of these countries have built chemical and biological R&D, generic and reverse engineering, and drug discovery capabilities. There have been tremendous barriers to entry but nevertheless a range of imitative approaches have evolved, with some significant scientific, health and industrial advances. Opportunities in India are in part created by the problems of maturity being faced by big pharmaceutical firms in developed countries. Big pharmaceutical firms are searching for novel approaches to retain a high value-added model of innovation for drug development. These difficulties provide opportunities for innovative companies in developing countries. This paper explores the challenges faced under these circumstances by Indian pharmaceutical companies. Are they attempting to 'catch-up' by chasing a failing model of innovation? Do they have an alternative model? Or can they become an important part of a transformed new global model of pharmaceutical innovation?
CORE (COnnecting REpositories)
CORE (COnnecting REpositories)
